Title:
METHOD FOR PRODUCING MYOCARDIAL STEM CELL USED FOR TREATMENT AND/OR PREVENTION OF CARDIAC ARREST
Document Type and Number:
WIPO Patent Application WO/2018/092839
Kind Code:
A1
Abstract:
[Problem] To provide: a novel myocardial stem cell for transplantation that enables maintaining of a therapeutic effect on and/or preventative effect against cardiac arrest for a prolonged period; a method for producing said myocardial stem cell; and a cell preparation containing said myocardial stem cell. [Solution] The present invention pertains to: a production method for a myocardial stem cell to be used for the treatment and/or prevention of cardiac arrest, the method comprising a step for introducing into a myocardial stem cell a complex of a mitochondria-targeted carrier and a mitochondria activating agent; a cell produced by said production method and a cell preparation containing same; and a liposome used to produce said cell. The present invention is able to provide a myocardial stem cell that is capable of maintaining a therapeutic effect by cell transplantation and/or a preventative effect thereby for a prolonged period.
More Like This:
Inventors:
HARASHIMA HIDEYOSHI (JP)
YAMADA YUMA (JP)
ABE JIRO (JP)
TAKEDA ATSUHITO (JP)
YAMADA YUMA (JP)
ABE JIRO (JP)
TAKEDA ATSUHITO (JP)
Application Number:
PCT/JP2017/041250
Publication Date:
May 24, 2018
Filing Date:
November 16, 2017
Export Citation:
Assignee:
UNIV HOKKAIDO NAT UNIV CORP (JP)
International Classes:
A61K45/00; A61K9/127; A61K31/05; A61K35/34; A61K47/24; A61K47/42; A61P9/04; C12N5/074
Foreign References:
| JP2007503461A | 2007-02-22 | |||
| JP5067733B2 | 2012-11-07 |
Other References:
GORBUNOV, NIKOLAI ET AL.: "Regeneration of infaarcted myocardium with resveratrol-modified cardiac stem cells", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 16, no. 1, 2012, pages 174 - 184, XP055488443
DANZ, ELIZABETH D. BROOKINS ET AL.: "Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization andthe Sirtl pathway", FREE RADICAL BIOLOGY & MEDICINE, vol. 46, 2009, pages 1589 - 1597, XP026099956
YAMADA, YUMA: "Development of the MITO-porter, a nano device for mitochondrial drug delivery via membrane fusion", vol. 134, no. 11, 2014, pages 1143 - 1155, XP055488460
KAWAMURA, ERIKO ET AL.: "Mitochondrial targeting functional peptides as potential devices for the mitochondrial deli very of a DF-MITO-Porter", MITOCHONDRION, vol. 13, 2013, pages 610 - 614, XP028764331
WANG, XIAO-XING ET AL.: "The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells", BIOMATERIALS, vol. 32, 2011, pages 5673 - 5687, XP028375328
ABE, JIRO ET AL.: "Cardiac progenitor cells activated by mitochondrial delivery of resveratrol enhance the survival of a doxorubicin-induced cardiomyopathy mouse model via the mitochondrial activation of a damaged myocardium", JOURNAL OF CONTROLLED RELEASE, vol. 269, 14 November 2017 (2017-11-14), pages 177 - 188, XP085322478
BOLLI, R. ET AL., LANCET, vol. 378, 2011, pages 1847 - 1857
MAKKAR, R. R. ET AL., LANCET, vol. 379, 2012, pages 895 - 904
ISHIGAMI, S. ET AL., CIRCULATION RESEARCH, vol. 116, 2015, pages 653 - 664
TAKEHARA, N. ET AL., J. AM. COLL. CARDIOL., vol. 52, 2008, pages 1858 - 65
DE ANGELIS, A. ET AL., CIRCULATION, vol. 121, 2010, pages 276 - 292
OH ET AL., PNAS, vol. 100, 2003, pages 12313 - 12318
ISHIGAMI ET AL., CIRC RES., vol. 116, 2015, pages 653 - 664
FUNAKOSHI S. ET AL., SCIENTIFIC REPORTS, vol. 6, 2016, pages 19111
IEDA M. ET AL., CELL, vol. 142, 2010, pages 375 - 386
KONG, BW. ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1625, 2003, pages 98 - 108
SZETO, H. H. ET AL., PHARM. RES., vol. 28, 2011, pages 2669 - 2679
WEISSIG, V. ET AL., J. CONTROL. RELEASE, vol. 75, 2001, pages 401 - 408
YAMADA, Y. ET AL., BIOCHIM BIOPHYS ACTA, vol. 1778, 2008, pages 423 - 432
YAMADA, Y. ET AL., MOL. THER., vol. 19, 2011, pages 1449 - 1456
KAWAMURA, E. ET AL., MITOCHONDRION, vol. 13, 2013, pages 610 - 614
G. F. KELSO ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 4588 - 4596
ANDRUS ET AL., TETRAHEDRON LETT., vol. 44, 2003, pages 4819 - 4822
ABE, J. ET AL., J. PHARM. SCI., vol. 105, 2016, pages 734 - 740
ZHANG ET AL., NATURE MEDICINE, vol. 18, 2012, pages 1639 - 1642
See also references of EP 3542822A4
DANZ, ELIZABETH D. BROOKINS ET AL.: "Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization andthe Sirtl pathway", FREE RADICAL BIOLOGY & MEDICINE, vol. 46, 2009, pages 1589 - 1597, XP026099956
YAMADA, YUMA: "Development of the MITO-porter, a nano device for mitochondrial drug delivery via membrane fusion", vol. 134, no. 11, 2014, pages 1143 - 1155, XP055488460
KAWAMURA, ERIKO ET AL.: "Mitochondrial targeting functional peptides as potential devices for the mitochondrial deli very of a DF-MITO-Porter", MITOCHONDRION, vol. 13, 2013, pages 610 - 614, XP028764331
WANG, XIAO-XING ET AL.: "The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells", BIOMATERIALS, vol. 32, 2011, pages 5673 - 5687, XP028375328
ABE, JIRO ET AL.: "Cardiac progenitor cells activated by mitochondrial delivery of resveratrol enhance the survival of a doxorubicin-induced cardiomyopathy mouse model via the mitochondrial activation of a damaged myocardium", JOURNAL OF CONTROLLED RELEASE, vol. 269, 14 November 2017 (2017-11-14), pages 177 - 188, XP085322478
BOLLI, R. ET AL., LANCET, vol. 378, 2011, pages 1847 - 1857
MAKKAR, R. R. ET AL., LANCET, vol. 379, 2012, pages 895 - 904
ISHIGAMI, S. ET AL., CIRCULATION RESEARCH, vol. 116, 2015, pages 653 - 664
TAKEHARA, N. ET AL., J. AM. COLL. CARDIOL., vol. 52, 2008, pages 1858 - 65
DE ANGELIS, A. ET AL., CIRCULATION, vol. 121, 2010, pages 276 - 292
OH ET AL., PNAS, vol. 100, 2003, pages 12313 - 12318
ISHIGAMI ET AL., CIRC RES., vol. 116, 2015, pages 653 - 664
FUNAKOSHI S. ET AL., SCIENTIFIC REPORTS, vol. 6, 2016, pages 19111
IEDA M. ET AL., CELL, vol. 142, 2010, pages 375 - 386
KONG, BW. ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1625, 2003, pages 98 - 108
SZETO, H. H. ET AL., PHARM. RES., vol. 28, 2011, pages 2669 - 2679
WEISSIG, V. ET AL., J. CONTROL. RELEASE, vol. 75, 2001, pages 401 - 408
YAMADA, Y. ET AL., BIOCHIM BIOPHYS ACTA, vol. 1778, 2008, pages 423 - 432
YAMADA, Y. ET AL., MOL. THER., vol. 19, 2011, pages 1449 - 1456
KAWAMURA, E. ET AL., MITOCHONDRION, vol. 13, 2013, pages 610 - 614
G. F. KELSO ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 4588 - 4596
ANDRUS ET AL., TETRAHEDRON LETT., vol. 44, 2003, pages 4819 - 4822
ABE, J. ET AL., J. PHARM. SCI., vol. 105, 2016, pages 734 - 740
ZHANG ET AL., NATURE MEDICINE, vol. 18, 2012, pages 1639 - 1642
See also references of EP 3542822A4
Attorney, Agent or Firm:
IP-ASSIST PATENT OFFICE (JP)
Download PDF:
Previous Patent: FOAM-MOLDED BODY AND METHOD FOR PRODUCING FOAM-MOLDED BODY
Next Patent: METHOD FOR PRODUCING p-XYLENE
Next Patent: METHOD FOR PRODUCING p-XYLENE